Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aptorum Group Limited (APM : NSDQ)

• Company Description    Aptorum Group Limited is a pharmaceutical company. It engaged in developing and commercializing therapeutic and diagnostic technologies to tackle unmet medical needs. The company's therapeutic and diagnostic project primarily includes neurology, infectious diseases, gastroenterology, oncology and other disease areas. Aptorum Group Limited is based in Connaught Road, Hong Kong. Number of Employees: 1

• Price / Volume Information    Yesterday's Closing Price: $0.94 Daily Weekly Monthly 20 Day Moving Average: 24,365 shares Shares Outstanding: 5.35 (millions) Market Capitalization: $5.04 (millions) Beta: -0.17 52 Week High: $4.74 52 Week Low: $0.46 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.18% -22.91% 12 Week 13.30% -4.38% Year To Date -66.36% -68.89%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 17 HANOVER SQUARE - LONDON,X0 W1S 1BN GBR ph: 44-20-8092-9299 fax: - investor.relations@aptorumgroup.com http://www.aptorumgroup.com

• General Corporate Information    Officers Ian Huen - Founder; Chief Executive Officer and Executive Dir Martin Siu - Head of Finance Charles Bathurst - Director Mirko Scherer - Director Justin Wu - Director Peer Information Aptorum Group Limited (GSAC) Aptorum Group Limited (CASI) Aptorum Group Limited (ALCD.) Aptorum Group Limited (OMNN) Aptorum Group Limited (CGPI.) Aptorum Group Limited (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: G6096M122 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 5.35 Most Recent Split Date: 1.00 (0.10:1) Beta: -0.17 Market Capitalization: $5.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.43 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 0.22 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 0.22 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 2.20 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©